VolitionRx Limited Announces Proof of Concept Data in Lymphoma and Leukemia

(3:42)

VolitionRx Breaks Down Supply Agreement of Nu.Q® Vet Cancer Tests with IDEXX Laboratories

(11:33)

VolitionRx Limited Announces Interim Results from a 680-Subject Clinical Trial in Colorectal Cancer

(5:26)

$VNRX VolitionRx Limited Q3 2024 Earnings Conference Call

(52:9)

Revolutionizing the Diagnosis of Life-altering Diseases 為重疾診斷技術帶來革命性突破 | VolitionRx (NYSE-A: VNRX)

(9:26)

Revolutionizing Healthcare: The Power of VolitionRX's Nucleosomics Platform

(31)

VolitionRx on Commercial Launch of Cancer Screen Test for Canines and Veterinary Market Opportunity

(10:3)

VolitionRx Limited Full Fiscal Year 2023 Financial Results and Business Update

(12:19)

VolitionRx – Commercializing the Nu.Q Vet Cancer Test: Webinar

(36:37)

VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update

(1:1econd)

VolitionRx Provides Update on Animal Health Blood Test Program, Licensing Deals and Focus for 2021

(10:16)

VolitionRx Limited 2019 Full Year Earnings Results

(7:12)

VolitionRx: Blood tests for cancers

(2:20)

VolitionRx Limited February 2021 Diamond Equity Presentation

(26:32)

VolitionRx Limited releases prostate cancer data, moving towards larger trials

(4:19)

You Need To Pay Attention To Volition Stock NYSE: VNRX

(1:48)

VolitionRx Ltd. (NYSE MKT: VNRX) Webcast | SNN Network

(24:51)

VolitionRx - 2024 Q3 Earnings Analysis

(5:15)

2024, in 4 minutes

(4:47)

Standard Form to Vertex Form - Quadratic Equations

(2:43)

VolitionRx Discusses $28 Million Licensing Deal with Heska and Focus for 2022

(4:53)

VolitionRx Limited Full Fiscal Year 2022 Financial Results and Business Update

(12:57)